Name | No. | For Patients with | Purpose |
---|---|---|---|
22-09 ADEPPT | 22-09 | Lung caner patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status[Cohort 1] or Elderly (≥70 years) [Cohort 2] |
The purpose of the trial is to assess the clinical efficacy of adagrasib treatment in patients with KRASG12C-mutant NSCLC, in patients who are elderly (≥70 years) or those with poor performance status (ECOG PS=2). |
DSSG Group: Lung
22-15 PLAN
Name | No. | For Patients with | Purpose |
---|---|---|---|
22-15 PLAN | 22-15 | Advanced or locally advanced Non-Small Cell Lung Cancer |
Purpose of this study is to evaluate whether plasma genotyping via an in-house next generation sequencing (NGS) panel, will identify actionable genomic alterations in patients with newly diagnosed advanced or locally advanced non-squamous NSCLC |
23-12 LATIFY
Name | No. | For Patients with | Purpose |
---|---|---|---|
23-12 LATIFY | 23-12 | patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy. |
The purpose of the study is to measure Overall Survival (OS). OS is defined as time from randomisation until the date of death due to any cause. The superiority of ceralasertib plus durvalumab combination therapy relative to docetaxel will be demonstrated by assessment of OS |
22-23 NeoCOAST-2
Name | No. | For Patients with | Purpose |
---|---|---|---|
22-23 NeoCOAST-2 | 22-23 | Early-Stage (II to IIIA) Non-small Cell Lung Cancer |
The purpose is to evaluate pathologic complete response in patients treated with Durvalumab with Oleclumab or Monalizumab. Also safety and tolerability of Durvalumab. |
BRAND
Name | No. | For Patients with | Purpose |
---|---|---|---|
BRAND | 23-11 | Non-Small Cell Lung Cancer |
The main purpose of this study is see if EBC(Exhaled Breath Condensate) can be used to check for biomarkers which are associated with a radiologic response to chemoimmunotherapy for patients with advanced NSCLC |
IMMUNO FERTILITY
Name | No. | For Patients with | Purpose |
---|---|---|---|
IMMUNO FERTILITY | 22-22 | Patients of Childbearing Potential who receive ICIs(Immune checkpoint inhibitors) for Cancer |
This study will use a number of tests to assess reproductive parameters in patients 1-2 years after they have received ICI therapy to observe the effect that ICI therapy may have on a patient’s fertility. |
AcceleRET-Lung
Name | No. | For Patients with | Purpose |
---|---|---|---|
AcceleRET-Lung | 20-21 | This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body. |
AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC). |
SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours
Name | No. | For Patients with | Purpose |
---|---|---|---|
SOURCE – LUNG: Stereotactic Ablative Radiation Therapy Of Ultracentral Lung Tumours | 18-33 | inoperable, early stage, high-risk ultracentrally located lung tumours. |
The purpose of the study is to determine the safety of the radiation therapy treatment regimen in terms of side effects experienced within one year after treatment which are related to the radiation therapy. |